Precision Oncology Market Share

APAC Market Forecast

By the end of 2037, Asia Pacific region is projected to hold over 43% precision oncology market share. The rising frequency of cancer incidence rates in the Asia Pacific region is one of the main factors for the significant growth driver for the precision oncology industry in the region.

 Due to the considerable concentration of cancer patients in the region, there is an increasing need for advanced and personalized cancer care. Precision oncology can adapt treatments based on individuals' specific genetic profiles, which has become important in tackling the region's diverse and increasing cancer frequency. According to studies, in 2022, India alone had more than 1.4 million new cancer cases and over 900,000 lakh deaths due to the disease. Consequently, in China a predicted 4 million cases of cancer were recorded in 2022.

In addition to that the growing awareness among patients about the benefits of precision oncology has created an increased demand for personalized cancer treatments in the Asia Pacific region. Patients are becoming more proactive in seeking information about genomic testing and targeted therapies, as a result, healthcare providers have started to incorporate precision oncology into their cancer care treatment.

North American Market Statistics

The precision oncology market in the North America region is foreseen to hold the second-largest share through 2037. The persistently high and increasing cancer incidence rates in North America underscore the pressing need for advanced and personalized cancer care solutions. Precision oncology, with its focus on tailoring treatments based on individual genetic profiles, becomes instrumental in addressing the rising cancer burden in the region.

The rapid adoption of genomic sequencing technologies, particularly NGS, is a key driver for precision oncology in North America. The substantial growth rate signifies the increasing integration of advanced sequencing techniques in clinical settings.